MX2022003346A - Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro. - Google Patents
Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro.Info
- Publication number
- MX2022003346A MX2022003346A MX2022003346A MX2022003346A MX2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A MX 2022003346 A MX2022003346 A MX 2022003346A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage forms
- bupropion
- enantiomerically enriched
- methods
- pure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2019/052210 WO2020061486A2 (en) | 2018-09-20 | 2019-09-20 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US202062971174P | 2020-02-06 | 2020-02-06 | |
| US202062978626P | 2020-02-19 | 2020-02-19 | |
| US202062992060P | 2020-03-19 | 2020-03-19 | |
| US16/830,637 US20200222339A1 (en) | 2018-09-20 | 2020-03-26 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| US16/907,691 US11433035B2 (en) | 2018-09-20 | 2020-06-22 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| PCT/US2020/046755 WO2021055124A1 (en) | 2019-09-20 | 2020-08-18 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003346A true MX2022003346A (es) | 2022-04-11 |
Family
ID=74884634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003346A MX2022003346A (es) | 2019-09-20 | 2020-08-18 | Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP4031121A4 (ko) |
| JP (2) | JP2022549192A (ko) |
| KR (1) | KR20220066930A (ko) |
| CN (1) | CN114423417A (ko) |
| AU (2) | AU2020349419B2 (ko) |
| BR (1) | BR112022005045A2 (ko) |
| CA (1) | CA3154718A1 (ko) |
| CO (1) | CO2022003126A2 (ko) |
| CR (1) | CR20220119A (ko) |
| EC (1) | ECSP22030119A (ko) |
| IL (1) | IL291514A (ko) |
| MX (1) | MX2022003346A (ko) |
| PE (1) | PE20221314A1 (ko) |
| WO (1) | WO2021055124A1 (ko) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2318960A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
| US6150420A (en) * | 1998-06-01 | 2000-11-21 | Theramax, Inc. | Method for enhanced brain delivery of bupropion |
| US20190216800A1 (en) * | 2013-11-05 | 2019-07-18 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
| MX2013014166A (es) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Enantiomeros activos y sus sales para el tratamiento de la obesidad. |
| US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
| SG11202008056SA (en) * | 2018-02-23 | 2020-09-29 | Axsome Therapeutics Inc | Dosage forms and methods for enantiomerically enriched or pure bupropion |
-
2020
- 2020-08-18 BR BR112022005045A patent/BR112022005045A2/pt unknown
- 2020-08-18 PE PE2022000441A patent/PE20221314A1/es unknown
- 2020-08-18 CN CN202080065520.4A patent/CN114423417A/zh active Pending
- 2020-08-18 KR KR1020227013095A patent/KR20220066930A/ko active Search and Examination
- 2020-08-18 CR CR20220119A patent/CR20220119A/es unknown
- 2020-08-18 AU AU2020349419A patent/AU2020349419B2/en active Active
- 2020-08-18 CA CA3154718A patent/CA3154718A1/en active Pending
- 2020-08-18 MX MX2022003346A patent/MX2022003346A/es unknown
- 2020-08-18 EP EP20866164.5A patent/EP4031121A4/en active Pending
- 2020-08-18 JP JP2022517743A patent/JP2022549192A/ja active Pending
- 2020-08-18 WO PCT/US2020/046755 patent/WO2021055124A1/en unknown
-
2022
- 2022-03-18 CO CONC2022/0003126A patent/CO2022003126A2/es unknown
- 2022-03-20 IL IL291514A patent/IL291514A/en unknown
- 2022-04-13 EC ECSENADI202230119A patent/ECSP22030119A/es unknown
-
2024
- 2024-01-05 AU AU2024200081A patent/AU2024200081A1/en active Pending
- 2024-02-22 JP JP2024025971A patent/JP2024059812A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020349419B2 (en) | 2023-11-02 |
| EP4031121A1 (en) | 2022-07-27 |
| AU2020349419A1 (en) | 2022-03-24 |
| JP2022549192A (ja) | 2022-11-24 |
| WO2021055124A1 (en) | 2021-03-25 |
| KR20220066930A (ko) | 2022-05-24 |
| ECSP22030119A (es) | 2022-05-31 |
| AU2024200081A1 (en) | 2024-01-25 |
| BR112022005045A2 (pt) | 2022-07-05 |
| CO2022003126A2 (es) | 2022-04-19 |
| IL291514A (en) | 2022-05-01 |
| CN114423417A (zh) | 2022-04-29 |
| PE20221314A1 (es) | 2022-09-07 |
| JP2024059812A (ja) | 2024-05-01 |
| EP4031121A4 (en) | 2022-11-30 |
| CR20220119A (es) | 2022-06-22 |
| CA3154718A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
| ZA202110659B (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| SG10201810888XA (en) | Compositions and methods comprising bupropion or related compounds and dextromethorphan | |
| MX2022005380A (es) | Composiciones que comprenden colina. | |
| JO3522B1 (ar) | تركيب صيدلاني يتألف من كريات حمراء تغلف إنزيم يعتمد على بيريدكسال الفوسفات والعامل المساعد له | |
| EP4295909A3 (en) | Carbidopa and l-dopa prodrugs and methods of use | |
| AU2018282105A1 (en) | Dosing of vibegron for treatment of overactive bladder | |
| GEP20247585B (en) | Furoindazole derivatives | |
| EP3755312A4 (en) | DOSAGE FORMS AND PROCESSES FOR ENANTIOMER ENHANCED OR PURE BUPROPION | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| MX2019010707A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| MX2021007142A (es) | Compuestos organicos. | |
| SG11201901617PA (en) | Azole compound ophthalmic preparation | |
| PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
| MX2022003346A (es) | Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro. | |
| EP3818981A4 (en) | SYNERGIC PHARMACEUTICAL COMBINATION OF THE ACTIVE ENANTIOMER S-KETOROLAC AND GABAPENTIN FOR THE TREATMENT OF NEUROPATHIC PAIN | |
| MX2018013324A (es) | Métodos y composiciones para el tratamiento del síndrome de rett. | |
| PH12021500016A1 (en) | Methods of reducing the risk of cardiovascular events in a subject | |
| EA202191907A1 (ru) | Применение вибегрона для лечения гиперактивного мочевого пузыря | |
| AU2017202335A1 (en) | Hangover cure. | |
| MX2013006332A (es) | Composiciones farmaceuticas orales para uso en dislipidemias. | |
| GR1008804B (el) | Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα | |
| UA108990C2 (en) | THE APPLICATION OF 4-AMINO-PIRIDIN NORRELIVER IN CREATIVE CREATIVES IN CANCER CANCER | |
| UA27828U (en) | Method for treating prosthetic stomatitis against the background metabolic syndrome |